Advanced Renal Cell Carcinoma Lenvatinib in Combination with Everolimus is approved as a Second-line Therapy

被引：0
|
作者：
Krampe-Scheidler, Anne
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷 / 10期
关键词：
INHIBITOR; E7080;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：666 / 667
页数：2
相关论文
共 50 条
  • [11] Lenvatinib in combination with everolimus in patients with advanced or metastatic renal cell carcinoma: A phase 1 study
    Matsubara, Nobuaki
    Naito, Yoichi
    Nakano, Kenji
    Fujiwara, Yutaka
    Ikezawa, Hiroki
    Yusa, Wataru
    Namiki, Masayuki
    Okude, Takashi
    Takahashi, Shunji
    INTERNATIONAL JOURNAL OF UROLOGY, 2018, 25 (11) : 922 - 928
  • [12] Second-line therapy for refractory renal-cell carcinoma
    Zustovich, Fable
    Lombardi, Giuseppe
    Nicoletto, Ornella
    Pastorelli, Davide
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2012, 83 (01) : 112 - 122
  • [13] ECONOMIC EVALUATION OF EVEROLIMUS AS SECOND-LINE TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN GREECE
    Solakidi, A.
    Kourlaba, G.
    Kontovinis, L.
    Koutsoukos, K.
    Bournakis, E.
    Boutis, A.
    Syrios, J.
    Tzovaras, A.
    Michailidi, C.
    Kalogeropoulou, M.
    Maniadakis, N.
    VALUE IN HEALTH, 2016, 19 (07) : A732 - A732
  • [14] Second-line therapy for advanced colorectal carcinoma
    Starling N.
    Cunningham D.
    Current Oncology Reports, 2005, 7 (3) : 173 - 180
  • [15] Clinical Benefit of Everolimus as Second-Line Therapy in Metastatic Renal Cell Carcinoma: The French Retrospective SECTOR Study
    Oudard, Stephane
    Joly, Florence
    Geoffrois, Lionnel
    Laguerre, Brigitte
    Houede, Nadine
    Barthelemy, Philippe
    Gross-Goupil, Marine
    Vano, Yann
    Lucidarme, Oliver
    Bidault, Francois
    Kelkouli, Nadia
    Slimane, Khemaies
    Escudier, Bernard
    CLINICAL GENITOURINARY CANCER, 2016, 14 (06) : E595 - E607
  • [16] Urothelial Carcinoma: Atezolizumab approved in the US as a Second-Line Therapy
    Dobler, Gabriele
    AKTUELLE UROLOGIE, 2019, 50 (01) : 16 - 16
  • [17] Re: Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
    Chang, Sam S.
    JOURNAL OF UROLOGY, 2021, 206 (06): : 1518 - 1519
  • [18] EVEROLIMUS AS SECOND-LINE THERAPY FOR METASTATIC RENAL CELL CARCINOMA. AN OBSERVATIONAL, RETROSPECTIVE STUDY FROM THE CAMPANIA REGION
    Rizzo, M.
    Facchini, G.
    Savastano, C.
    Di Lorenzo, G.
    De Lucia, L.
    Maiorino, L.
    Casale, B.
    Grimaldi, G.
    Formato, R.
    Febbraro, A.
    Pappagallo, G.
    Carteni, G.
    ANTICANCER RESEARCH, 2014, 34 (05) : 2676 - 2677
  • [19] Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy
    Guida, Annalisa
    Albiges, Laurence
    Derosa, Lisa
    Loriot, Yohann
    Massard, Christophe
    Fizazi, Karim
    Escudier, Bernard
    CLINICAL GENITOURINARY CANCER, 2017, 15 (06) : E1081 - E1088
  • [20] Cost-Effectiveness of Everolimus for Second-Line Treatment of Metastatic Renal Cell Carcinoma in Serbia
    Mihajlovic, Jovan
    Pechlivanoglou, Petros
    Sabo, Ana
    Tomic, Zdenko
    Postma, Maarten J.
    CLINICAL THERAPEUTICS, 2013, 35 (12) : 1909 - 1922
12345